Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMALTHEA: AZD7798 in moderate to severe Crohn's disease
2023-510487-12-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 30
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing AZD7798 with Placebo (2 arms). Primary endpoint: CDAI remission. Planned start Nov 2024; status: authorised.
02
Drugs
azd7798
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-510487-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510487-12-00.